Sign In
Buy GH
$127.03
-3.14 (-2.41%)
At Close: Jun 03, 2026
Guardant Health: A Promising Player in the Liquid Biopsy Market
07:30pm, Friday, 16'th May 2025
Explore the exciting world of Guardant Health (GH 0.54%) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and pot
TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year
09:20am, Thursday, 08'th May 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Today TIME named to its 2025 TIME100 Health list co-CEOs Helmy Eltoukhy and AmirAli Talasaz of Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology comp
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:05pm, Wednesday, 07'th May 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on April 22, 2025, the Compensation Committee of Guardant's Board of
Guardant Health: Tailwinds Are Beginning To Impact The Financials
04:33pm, Thursday, 01'st May 2025
Guardant Health handily beat Q1 expectations and meaningfully increased full-year growth expectations. Guardant also continues to benefit from positive developments in relation to pricing, regulatory
Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript
10:25pm, Wednesday, 30'th Apr 2025
Guardant Health, Inc. (NASDAQ:GH ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Zarak Khurshid - Vice President of Investor Relations Helmy Eltoukhy - Chairman and C
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
06:55pm, Wednesday, 30'th Apr 2025
Guardant Health (GH) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.46 per share a year ago.
Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
04:05pm, Wednesday, 30'th Apr 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today reported financial results for the quarter ended March 31, 2025. First Quarter 2025
Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types
04:20pm, Tuesday, 29'th Apr 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, presented data today from a study showing that its methylation-based Shield™ multi-cance
PALO ALTO, Calif.--(BUSINESS WIRE)--Throughout release, "exome-wide" should read as "genome-wide". The updated release reads: GUARDANT HEALTH LAUNCHES GUARDANT360 TISSUE, FIRST TISSUE MOLECULAR PROFIL
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the launch of Guardant360® Tissue, the first molecular profiling test for
Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline
11:07am, Wednesday, 23'rd Apr 2025
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR
08:05am, Tuesday, 22'nd Apr 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will present 18 abstracts, including four oral sessions, showcasing adv
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
04:05pm, Thursday, 10'th Apr 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market c
Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada
08:05am, Thursday, 03'rd Apr 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has entered into an agreement with Bayshore HealthCare, a leading home
4 Healthcare Stocks With Massive Gains—and More to Come
07:16am, Saturday, 29'th Mar 2025
The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks ar
